Literature DB >> 19659648

Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis.

Yasuhiko Kitasato1, Yoshiaki Tao, Tomoaki Hoshino, Kousuke Tachibana, Naoko Inoshima, Makoto Yoshida, Shohei Takata, Kan Okabayashi, Masayuki Kawasaki, Tomoaki Iwanaga, Hisamichi Aizawa.   

Abstract

BACKGROUND AND
OBJECTIVE: The usefulness of two tests in the serodiagnosis of chronic pulmonary aspergillosis (CPA) was compared. The tests were the serum Aspergillus galactomannan antigen test (Platelia (R) Aspergillus) by enzyme-linked immunoassay (EIA) using old and new cut-off indexes, and the Aspergillus precipitating antibody test.
METHODS: Both Aspergillus-precipitating antibody and Platelia Aspergillus EIA positivity were measured in the sera of 28 patients at the time of diagnosis of CPA.
RESULTS: Serum Aspergillus precipitating antibody positivity was 89.3% (25/28) in CPA patients. Serum Platelia Aspergillus EIA positivity was 21.4% (6/28) using the old cut-off index (> or =1.5) and 50% (14/28) using the new cut-off index (> or =0.5)-still less than that for Aspergillus precipitating antibody. Three of the 28 CPA patients had positive reactions in the Platelia Aspergillus EIA using the old cut-off index but not in the Aspergillus precipitating antibody test. Positivity for (1,3) beta-d glucan was 15.4%, and that for culture on CHROMagar Candida was 17.9%. One patient with pulmonary actinomycosis had a false-positive reaction in the Platelia Aspergillus test with the new cut-off index.
CONCLUSIONS: For the diagnosis of CPA, Aspergillus precipitating antibody testing is more sensitive than the Platelia Aspergillus EIA, even with the new cut-off index. False-positive reactions are observed with the Platelia Aspergillus EIA in patients with conditions such as pulmonary actinomycosis. Results should be interpreted with care when patients are positive for the Platelia Aspergillus EIA but negative for Aspergillus precipitating antibody.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19659648     DOI: 10.1111/j.1440-1843.2009.01548.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  17 in total

1.  Utility of Serum and Bronchoalveolar Lavage Fluid Galactomannan in Diagnosis of Chronic Pulmonary Aspergillosis.

Authors:  Inderpaul Singh Sehgal; Sahajal Dhooria; Hansraj Choudhary; Ashutosh Nath Aggarwal; Mandeep Garg; Arunaloke Chakrabarti; Ritesh Agarwal
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

2.  Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran.

Authors:  M T Hedayati; Y Azimi; A Droudinia; B Mousavi; A Khalilian; N Hedayati; D W Denning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-24       Impact factor: 3.267

3.  Evaluation of Aspergillus-Specific Lateral-Flow Device Test Using Serum and Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis.

Authors:  Takahiro Takazono; Yuya Ito; Masato Tashiro; Keitaro Nishimura; Tomomi Saijo; Kazuko Yamamoto; Yoshifumi Imamura; Taiga Miyazaki; Katsunori Yanagihara; Hiroshi Mukae; Koichi Izumikawa
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

4.  Usefulness of Two Aspergillus PCR Assays and Aspergillus Galactomannan and β-d-Glucan Testing of Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis.

Authors:  Naohisa Urabe; Susumu Sakamoto; Go Sano; Junko Suzuki; Akira Hebisawa; Yasuhiko Nakamura; Kazuya Koyama; Yoshikazu Ishii; Kazuhiro Tateda; Sakae Homma
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

5.  Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series.

Authors:  G Cucchetto; A Cazzadori; M Conti; G L Cascio; P Braggio; E Concia
Journal:  Infection       Date:  2014-11-29       Impact factor: 3.553

Review 6.  [Aspergillus in airway material : Ignore or treat?]

Authors:  H J F Salzer; C Lange; M Hönigl
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

7.  Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.

Authors:  T Saito; S Fujiuchi; Y Tao; Y Sasaki; K Ogawa; K Suzuki; A Tada; M Kuba; T Kato; M Kawabata; A Kurashima; M Sakatani
Journal:  Infection       Date:  2012-09-07       Impact factor: 3.553

Review 8.  Galactomannan detection for invasive aspergillosis in immunocompromised patients.

Authors:  Mariska M G Leeflang; Yvette J Debets-Ossenkopp; Junfeng Wang; Caroline E Visser; Rob J P M Scholten; Lotty Hooft; Henk A Bijlmer; Johannes B Reitsma; Mingming Zhang; Patrick M M Bossuyt; Christina M Vandenbroucke-Grauls
Journal:  Cochrane Database Syst Rev       Date:  2015-12-30

9.  Evaluation of a Quantitative Serological Assay for Diagnosing Chronic Pulmonary Aspergillosis.

Authors:  Satoru Fujiuchi; Yuka Fujita; Hokuto Suzuki; Kazushi Doushita; Hikaru Kuroda; Masaaki Takahashi; Yasuhiro Yamazaki; Tadakatsu Tsuji; Toshiaki Fujikane; Shinobu Osanai; Takaaki Sasaki; Yoshinobu Ohsaki
Journal:  J Clin Microbiol       Date:  2016-03-23       Impact factor: 5.948

Review 10.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.